NCT01110720

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 313 (actual)
• Sponsor: Allon Therapeutics · Industry
• Sex: All
• Age: 41 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy.

Detailed description

A Phase 2/3,Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

Conditions

• Progressive Supranuclear Palsy

Interventions

Type	Name	Description
DRUG	Davunetide	Davunetide Nasal Spray 30 mg BID IN 52 weeks
DRUG	Placebo	Placebo Nasal Spray BID IN 52 weeks

Timeline

• Start date: 2010-10-01
• Primary completion: 2012-11-01
• Completion: 2012-12-01
• First posted: 2010-04-27
• Last updated: 2013-01-17

Locations

48 sites across 6 countries: United States, Australia, Canada, France, Germany, United Kingdom